The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The revenues this quarter are in line with the outlook we envisaged for the year
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Inspection included drug device combinations covering our recent filing in nasal sprays domain
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
Subscribe To Our Newsletter & Stay Updated